Agendia has appointed William Audeh as chief medical officer. Audeh will report to CEO Mark Straley and is responsible for translating complex laboratory science and personalized medicine diagnostics into actionable, patient-centered solutions for clinicians. Prior to joining Agendia, he served as the director of the Cedars-Sinai Cancer Center, medical director of the Wasserman Breast Cancer Risk Reduction Program, and associate clinical professor of medicine at the University of California, Los Angeles David Geffen School of Medicine. Audeh has also been the principal investigator on a wide variety of both national and international clinical and translational trials, and has authored numerous publications in the field of breast cancer, cancer genomics, and targeted cancer therapy.
Personal Genome Diagnostics has appointed Douglas Ward as CEO and a member of the board of directors. Ward joins PGDx from Roche, where he most recently served as VP of companion diagnostics for Ventana Medical Systems, a Roche subsidiary. Prior to his work at Roche, he served as president and general manager of commercial operations for GE Healthcare's Life Sciences business in the Americas. Before that, he held positions of increasing responsibility at Bayer Healthcare, including country head for UK and Ireland, and VP of marketing and scientific affairs for Bayer Molecular Diagnostics.
Castle Biosciences has appointed Bernhard Spiess as chief operating officer. Bernhard most recently served as vice president of product management for both clinical chemistry and infectious diseases at Beckman Coulter. He spent 23 years working at Beckman Coulter and played key leadership roles in the development and commercialization of various platforms. Earlier in his career, Bernhard worked for Sanofi Diagnostics Pasteur and Abbott Diagnostics.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.